IPD spinout Neoleukin merges with Aquinox for NASDAQ listing

Neoleukin thinks its merger with Aquinox announced Tuesday will enable the de novo protein design newco to submit an IND for its IL-2 mimetic and announce additional preclinical programs by the end of

Read the full 337 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE